Venous thromboembolism in multiple sclerosis: a report of two cases with pulmonary embolism on dimethyl fumarate and available data from adverse event reporting systems. Time to include disease modifying drugs in the equation?

•MS has been associated with an increased risk for VTE.•In our cases, DMF was a possible triggering factor for PE.•High number of VTE cases was found on adverse event reporting systems.•Further work is needed to establish DMTs role in VTE.

Saved in:
Bibliographic Details
Published in:Clinical neurology and neurosurgery 2020-05, Vol.192, p.105726, Article 105726
Main Authors: Papathanasiou, Athanasios, Abdel-Fahim, Rasha, Gilmore, Christopher, Evangelou, Nikos
Format: Article
Language:English
Subjects:
Dimethyl fumarate
Disease modifying treatment
Echocardiography
Embolism
FDA approval
Gender
Health risk assessment
Magnetic resonance imaging
Multiple sclerosis
Myeloproliferative diseases
Neurology
Pain
Patients
Pelvis
Pulmonary embolism
Pulmonary embolisms
Thromboembolism
Thrombophilia
Thrombosis
Venous thromboembolism
α-Interferon
β-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•MS has been associated with an increased risk for VTE.•In our cases, DMF was a possible triggering factor for PE.•High number of VTE cases was found on adverse event reporting systems.•Further work is needed to establish DMTs role in VTE.
ISSN:0303-8467
1872-6968
DOI:10.1016/j.clineuro.2020.105726